Evogene Ltd. balance sheet

At the end of fiscal 2025, Evogene Ltd. had total assets of $20.0m, total liabilities of $8.1m and shareholders' equity of −$82,000. It held $13.0m in cash against $0 of debt: net cash of $13.0m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evogene Ltd.: balance sheet, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	10	3	3	6	35	46	32	29	21	15	13
Inventory	—	—	—	—	—	0	0	1	0	2	0
Total current assets	—	89	73	55	49	52	57	38	34	22	16
Total assets	—	96	78	59	71	72	76	56	51	40	20
Total current liabilities	—	5	5	5	6	10	7	6	7	19	3
Total debt	0	0	0	0	0	0	0	0	0	0	0
Total liabilities	—	—	—	—	—	—	—	—	22	25	8
Shareholders' equity	104	87	69	50	50	46	54	28	12	−1	−0
Non-controlling interests and other (assets − liabilities − equity)	—	—	—	—	—	—	—	—	17	16	12
Net debt (negative = net cash)	−10	−3	−3	−6	−35	−46	−32	−29	−21	−15	−13
Shares outstanding	—	—	—	—	—	—	—	—	5m	7m	9m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: DBVT vs EVGN DYAI vs EVGN ALGS vs EVGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evogene Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evogene Ltd.